BDAZ, remarkable and thanks.

Obviously I don't understand the science but I get a clear impression that the BET inhibitor platforms developed by RVX and Zenith seem to have remarkable properties in not just a linear manner but in a wide ranging interactive set of effects on multiple levels and achieving this with minimal or little toxicity.

ZEN 3694 seems to have the potential to work on it's own as well as with standard of care drugs and it seems to have potential beyond castration resistant metastatic prostate cancer.

I've posted this idea before but I have the impression that RVX and Zenith in their approaches to BET inhibition seem to have discovered, in a sense, a kind of flexible factory for creating compounds to address different indications and the compounds almost seem natural to the biological condition (unlike chemicals like bleomycen and vinblastin type of cancer fighters). This seems like a gold mine for almost unlimited exploration far beyond just apabetalone and zen-3694.

No wonder Eastern Capital, NGN and Hepalink are heavily invested. This is gold IMHO particularly with the failures of CEPT inhibitors to date.

Thanks again!

Toinv